FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Wearable medical devices are changing healthcare delivery by shifting care beyond traditional settings and bringing it closer to patients’ daily lives. By offering continuous monitoring, promoting patient engagement and supporting remote interventions, these technologies are becoming an essential part of…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us